Literature DB >> 25661585

Nanoparticle diffusion within intestinal mucus: Three-dimensional response analysis dissecting the impact of particle surface charge, size and heterogeneity across polyelectrolyte, pegylated and viral particles.

Muthanna Abdulkarim1, Nuria Agulló2, Beatrice Cattoz3, Peter Griffiths3, Andreas Bernkop-Schnürch4, Salvador Gómez Borros2, Mark Gumbleton5.   

Abstract

Multiple particle tracking (MPT) methodology was used to dissect the impact of nanoparticle surface charge and size upon particle diffusion through freshly harvested porcine jejunum mucus. The mucus was characterised rheologically and by atomic force microscopy. To vary nanoparticle surface charge we used a series of self-assembly polyelectrolyte particles composed of varying ratios of the negatively charged polyacrylic acid polymer and the positively charged chitosan polymer. This series included a neutral or near-neutral particle to correspond to highly charged but near-neutral viral particles that appear to effectively permeate mucus. In order to negate the confounding issue of self-aggregation of such neutral synthetic particles a sonication step effectively reduced particle size (to less than 340 nm) for a sufficient period to conduct the tracking experiments. Across the polyelectrolyte particles a broad and meaningful relationship was observed between particle diffusion in mucus (×1000 difference between slowest and fastest particle types), particle size (104-373 nm) and particle surface charge (-29 mV to +19.5 mV), where the beneficial characteristic promoting diffusion was a neutral or near-neutral charge. The diffusion of the neutral polyelectrolyte particle (0.02887 cm S(-1)×10(-9)) compared favourably with that of a highly diffusive PEGylated-PLGA particle (0.03182 cm(2) S(-1)×10(-9)), despite the size of the latter (54 nm diameter) accommodating a reduced steric hindrance with the mucin network. Heterogeneity of particle diffusion within a given particle type revealed the most diffusive 10% sub-population for the neutral polyelectrolyte formulation (5.809 cm(2) S(-1)×10(-9)) to be faster than that of the most diffusive 10% sub-populations obtained either for the PEGylated-PLGA particle (4.061 cm(2) S(-1)×10(-9)) or for a capsid adenovirus particle (1.922 cm(2) S(-1)×10(-9)). While this study has used a simple self-assembly polyelectrolyte system it has substantiated the pursuance of other polymer synthesis approaches (such as living free-radical polymerisation) to deliver stable, size-controlled nanoparticles possessing a uniform high density charge distribution and yielding a net neutral surface potential. Such particles will provide an additional strategy to that of PEGylated systems where the interactions of mucosally delivered nanoparticles with the mucus barrier are to be minimised.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Diffusion; Mucus; Multiple particle tracking; Nanoparticles; Polyelectrolyte; Virus

Mesh:

Substances:

Year:  2015        PMID: 25661585     DOI: 10.1016/j.ejpb.2015.01.023

Source DB:  PubMed          Journal:  Eur J Pharm Biopharm        ISSN: 0939-6411            Impact factor:   5.571


  20 in total

1.  Minimizing biases associated with tracking analysis of submicron particles in heterogeneous biological fluids.

Authors:  Ying-Ying Wang; Kenetta L Nunn; Dimple Harit; Scott A McKinley; Samuel K Lai
Journal:  J Control Release       Date:  2015-10-18       Impact factor: 9.776

Review 2.  Nanoparticles for oral delivery: Design, evaluation and state-of-the-art.

Authors:  Abhijit A Date; Justin Hanes; Laura M Ensign
Journal:  J Control Release       Date:  2016-06-09       Impact factor: 9.776

Review 3.  Physicochemical properties of mucus and their impact on transmucosal drug delivery.

Authors:  Jasmim Leal; Hugh D C Smyth; Debadyuti Ghosh
Journal:  Int J Pharm       Date:  2017-09-14       Impact factor: 5.875

4.  Peptides as surface coatings of nanoparticles that penetrate human cystic fibrosis sputum and uniformly distribute in vivo following pulmonary delivery.

Authors:  Jasmim Leal; Xiujuan Peng; Xinquan Liu; Dhivya Arasappan; Dennis C Wylie; Sarah H Schwartz; Jason J Fullmer; Bennie C McWilliams; Hugh D C Smyth; Debadyuti Ghosh
Journal:  J Control Release       Date:  2020-03-31       Impact factor: 9.776

5.  Anti-PEG antibodies alter the mobility and biodistribution of densely PEGylated nanoparticles in mucus.

Authors:  Christine E Henry; Ying-Ying Wang; Qi Yang; Thuy Hoang; Sumon Chattopadhyay; Timothy Hoen; Laura M Ensign; Kenetta L Nunn; Holly Schroeder; Justin McCallen; Thomas Moench; Richard Cone; Steve R Roffler; Samuel K Lai
Journal:  Acta Biomater       Date:  2016-07-14       Impact factor: 8.947

Review 6.  Nanocomposite systems for precise oral delivery of drugs and biologics.

Authors:  Valentina Andretto; Annalisa Rosso; Stéphanie Briançon; Giovanna Lollo
Journal:  Drug Deliv Transl Res       Date:  2021-02-03       Impact factor: 4.617

Review 7.  The pharmacology of plant virus nanoparticles.

Authors:  Christian Isalomboto Nkanga; Nicole F Steinmetz
Journal:  Virology       Date:  2021-01-28       Impact factor: 3.616

8.  Zein-based nanocarriers for the oral delivery of insulin. In vivo evaluation in Caenorhabditis elegans.

Authors:  Ana L Martínez-López; Carlos J González-Navarro; José L Vizmanos; Juan M Irache
Journal:  Drug Deliv Transl Res       Date:  2021-01-29       Impact factor: 4.617

9.  In vivo testing of mucus-permeating nanoparticles for oral insulin delivery using Caenorhabditis elegans as a model under hyperglycemic conditions.

Authors:  Ana L Martínez-López; Carlos J González-Navarro; Paula Aranaz; José L Vizmanos; Juan M Irache
Journal:  Acta Pharm Sin B       Date:  2021-03-01       Impact factor: 11.413

10.  Development of tamoxifen-loaded surface-modified nanostructured lipid carrier using experimental design: in vitro and ex vivo characterisation.

Authors:  Ganesan Poovi; Narayanasamy Damodharan
Journal:  IET Nanobiotechnol       Date:  2020-06       Impact factor: 1.847

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.